The investigational drug rimonabant has churned up a lot of excitement thanks to its success so far in producing weight loss and smoking cessation during several clinical trials.
In this trial, 1045 individuals with type 2 diabetes were randomized to receive either 5 mg of rimonabant, 20 mg of rimonabant, or placebo. All patients were on non-insulin diabetic therapy (metformin or a sulfonylurea drug). After 1 year, the group taking the higher dose of rimonabant had significant reductions in weight and waist circumference.
They also had significantly reduced hemoglobin A1C levels, a finding that reflects improved glucose control. Finally, they had significantly improved HDL cholesterol and triglyceride levels, and reduced systolic blood pressure.
These results of RIO-Diabetes appear similar to the results reported in earlier trials with rimonabant - but for the first time the effect of this drug now has been documented in patients with diabetes, a group typically particularly resistant to weight loss.
Having brought a major revolution in the weight loss drugs market, Rimonabant better known as Acomplia now is a sigh of relief for patients suffering from type 2 diebetes in addition to obese populace. Fabricated by the French pharmaceutical giant Sanofi-Aventis, the marvelous preparation has an atypical potential to reduce body weight simultaneously with blood fats and blood glucose in people with type 2 diabetes, as per the study published by the British health journal, The Lancet.
Type 2 diabetes is a potentially severe disease which commonly emerges at the stage of adulthood. In the past two decades, the total number of people falling prey to this intimidating disease has escalated on an alarming rate. And obesity, high levels of harmful cholesterol and high blood pressure are few risk-factors that have been shoring up type2 diabetes patient’s graph every year.
Under the study sponsored by the Rimonabant diet pills maker, Sanofi-Aventis and conducted over 1,047 obese diabetes patients and overweight in 11 countries including Europe, North and South America, the effectiveness of Rimonabant weight loss pills was tested and compared with an analogous weight loss pill called Placebo for one year. In the conclusion, patients who were making use of rimonabant lost more weight when compared with Placebo users. In addition they also reported remarkable improvement in their appetite and blood glucose level than the Placebo users. Although Rimonabant diet pills were well endured by most, but few patients have complained about the onset of anxiety, nausea, and vomiting.
The study definitely is a major landmark considering the dearth of a real-time solution for type 2 diabetes at present. As all available drugs only can improve the blood glucose and lead to weight gain simultaneously, Rimonabant diet pills will be a credible alternative to keep type 2 diabetes in control.
